Cargando…
Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455018/ https://www.ncbi.nlm.nih.gov/pubmed/36077696 http://dx.doi.org/10.3390/cancers14174160 |
_version_ | 1784785489643962368 |
---|---|
author | Zhao, Yueshui Deng, Jian Rao, Shuangfeng Guo, Sipeng Shen, Jing Du, Fukuan Wu, Xu Chen, Yu Li, Mingxing Chen, Meijuan Li, Xiaobing Li, Wanping Gu, Li Sun, Yuhong Zhang, Zhuo Wen, Qinglian Xiao, Zhangang Li, Jing |
author_facet | Zhao, Yueshui Deng, Jian Rao, Shuangfeng Guo, Sipeng Shen, Jing Du, Fukuan Wu, Xu Chen, Yu Li, Mingxing Chen, Meijuan Li, Xiaobing Li, Wanping Gu, Li Sun, Yuhong Zhang, Zhuo Wen, Qinglian Xiao, Zhangang Li, Jing |
author_sort | Zhao, Yueshui |
collection | PubMed |
description | SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. ABSTRACT: Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. |
format | Online Article Text |
id | pubmed-9455018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94550182022-09-09 Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges Zhao, Yueshui Deng, Jian Rao, Shuangfeng Guo, Sipeng Shen, Jing Du, Fukuan Wu, Xu Chen, Yu Li, Mingxing Chen, Meijuan Li, Xiaobing Li, Wanping Gu, Li Sun, Yuhong Zhang, Zhuo Wen, Qinglian Xiao, Zhangang Li, Jing Cancers (Basel) Review SIMPLE SUMMARY: Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. ABSTRACT: Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. MDPI 2022-08-27 /pmc/articles/PMC9455018/ /pubmed/36077696 http://dx.doi.org/10.3390/cancers14174160 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhao, Yueshui Deng, Jian Rao, Shuangfeng Guo, Sipeng Shen, Jing Du, Fukuan Wu, Xu Chen, Yu Li, Mingxing Chen, Meijuan Li, Xiaobing Li, Wanping Gu, Li Sun, Yuhong Zhang, Zhuo Wen, Qinglian Xiao, Zhangang Li, Jing Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title_full | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title_fullStr | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title_full_unstemmed | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title_short | Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges |
title_sort | tumor infiltrating lymphocyte (til) therapy for solid tumor treatment: progressions and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9455018/ https://www.ncbi.nlm.nih.gov/pubmed/36077696 http://dx.doi.org/10.3390/cancers14174160 |
work_keys_str_mv | AT zhaoyueshui tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT dengjian tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT raoshuangfeng tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT guosipeng tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT shenjing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT dufukuan tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT wuxu tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT chenyu tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT limingxing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT chenmeijuan tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT lixiaobing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT liwanping tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT guli tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT sunyuhong tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT zhangzhuo tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT wenqinglian tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT xiaozhangang tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges AT lijing tumorinfiltratinglymphocytetiltherapyforsolidtumortreatmentprogressionsandchallenges |